GlassScriptPhysician profile
Rachel M Koster
NPI 1437469830
$1,818.25
in general payments reported to CMS, 2019-2025
20 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $255 · 2023: $534 · 2024: $492 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.32 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.09 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $259.99 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $181.60 | 2022-2023 | |
| Pfizer INC. | $151.63 | 2022-2025 | |
| Novo Nordisk INC | $131.86 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $112.98 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $83.28 | 2021-2024 | Xospata, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.55 | 2021-2024 | Jardiance |
| Amgen INC. | $61.42 | 2021-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $37.73 | 2023 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $24.55 | 2025 | |
| Sumitomo Pharma America, INC. | $24.04 | 2023 | Gemtesa |
| Fennec Pharmaceuticals, INC. | $22.97 | 2025 | Fyarro |
| Allergan, INC. | $22.43 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $22.01 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $20.28 | 2025 | Korlym |
| Medtronic, INC. | $17.12 | 2023 | Closurefast |
| Idorsia Pharmaceuticals US INC | $13.61 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Koster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.